202223 Sep

Leuko Lands $5M Series A

Summary

BOSTON, MA, Leuko, an MIT startup developing white blood cell (WBC) monitoring, announced a first closing of $5 million for their Series A round. Leuko, an MIT startup developing PointCheck, the first solution that enables at-home noninvasive white blood cell (WBC) monitoring, announced a first closing of $5 million for their Series A round. Leuko is a startup spun out from MIT and the Madrid M+Vision Consortium and founded by Carlos Castro-Gonzalez, Ian Butterworth, Aurelien Bourquard, and Alvaro Sanchez-Ferro. They are developing a platform technology, PointCheckTM, that combines optics and AI to make noninvasive blood testing easier, faster and more accessible than state-of-the art solutions. For its first application, Leuko aims to improve clinical outcomes for >2M cancer chemotherapy patients a year, reduce their chemotherapy-related hospital readmissions by 50% and save >$6B annually in healthcare cost.

Source: Vcnewsdaily

Funding

$5M
Amount
Sep 23 2022
Date
-
Investor
-
Company

Classifications

Companies